Introduction
============

Sentinel lymph node biopsy (SLNB) is a standard procedure for managing patients with clinical node-negative breast cancer and it lowers surgical morbidity and improves quality of life compared to axillary lymph node dissection (ALND) while providing similar survival rates \[[@b1-crt-2017-210],[@b2-crt-2017-210]\]. However, the oncologic safety of SLNB remains controversial in patients with cytology-proven node-positive disease at presentation that is converted to clinical node-negative status after receiving neoadjuvant chemotherapy (NCT). Nodal metastasis can be eradicated by NCT in up to approximately 40% of patients with positive axillary lymph node (ALN) metastasis at diagnosis \[[@b3-crt-2017-210],[@b4-crt-2017-210]\], but the possible effects of NCT are alterations or disruptions of lymphatic vessels or nonuniform tumor regression of metastatic ALNs, which can limit the usefulness of SLNB in these patients \[[@b5-crt-2017-210]\].

Several prospective clinical trials were undertaken to determine the accuracy of SLNB after NCT in patients with clinical or histological node-positive disease and the overall false-negative rate (FNR) of SLNB was 14.2% in the SENTinel NeoAdjuvant (SENTINA) study, 12.6% in the American College of Surgeons Oncology Group (ACOSOG) Z1071 (Alliance) trial, and 13.3% in the Sentinel Node Biopsy Following Neoadjuvant Chemotherapy (SN FNAC) trial \[[@b6-crt-2017-210]-[@b8-crt-2017-210]\]. In cases where dual tracers were used, \> 2 sentinel lymph nodes (SLNs) were retrieved, or immunohistochemistry was used; however, FNRs \< 10% were clinically acceptable for SLNB \[[@b4-crt-2017-210]\]. Thus, the National Comprehensive Cancer Network (NCCN) guidelines recommend SLNB or ALND if biopsy-proven metastatic ALNs are converted to clinically node-negative status after preoperative systemic therapy \[[@b9-crt-2017-210]\]. Importantly, the NCCN guidelines emphasize that marking sampled ALNs with a clip or tattoo before NCT can improve the diagnostic performance of SLNB \[[@b10-crt-2017-210],[@b11-crt-2017-210]\].

A biopsy-proven metastatic ALN has to be marked if targeted axillary dissection is to be performed after NCT and this marking has to take place by an experienced radiologist with specialized equipment such as a clip \[[@b12-crt-2017-210]\]. Preoperative localization with a wire or radioactive seed is also necessary and this additional invasive procedure might be uncomfortable for patients. Furthermore, clinicians must also check possible clip migration and determine the radiation safety of the radioactive seed \[[@b4-crt-2017-210]\]. In comparison, additional localization is not required for the tattooing technique of positive node although limited studies have been reported since its introduction \[[@b11-crt-2017-210]\]. The diagnostic performance of the tattooing procedure incorporated into SLNB should be studied with this background in mind. In addition, marked metastatic ALN before NCT is not always detected as hot and/or blue nodes at surgery.

For clarifying the association between tattooed ALN at diagnosis and dual traced nodes after NCT, SLNB was considered as results of hot/blue ALNs retrieved alone and modified SLNB was defined as findings of dual traced or residual marked, suspiciously enlarged nodes in this study.

The main aims of the present study were primarily to investigate whether black tattoo injected in cytology-proven metastatic ALN at presentation could be detected intraoperatively in patients treated with NCT and to examine the feasibility of charcoal tattooing in breast cancers. The second was to evaluate the diagnostic performance of SLNB with or without marking the biopsy-proven metastatic ALN by calculating the detection rate, sensitivity, FNR, negative predictive value (NPV), and accuracy. The last was to determine the concordance between charcoal-tattooed ALN and SLNs detected by radioisotopes and blue dye. If a discordance was found, we tried to identify which clinicopathological parameters were associated with the discordance.

Materials and Methods
=====================

1. Patient enrollment
---------------------

Twenty patients with clinical T1-T3 breast cancer at diagnosis who received NCT between October 2015 and July 2016 were prospectively enrolled from Yonsei Cancer Center, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea. All patients had cytology-proven ALN metastases prior to NCT. Patients with a past history of allergic reaction to charcoal agents, inflammatory or T4 breast carcinoma, or stage IV cancer at diagnosis were excluded. At presentation, all patients with clinically enlarged ALNs or with radiologically suspicious nodal findings of loss of fatty hilum, cortical thickening \> 3 mm, round shape, markedly hypoechoic cortex, or increased peripheral blood flow underwent ultrasound-guided fine needle aspiration cytology of the most suspicious or largest ALN to confirm the presence of metastasis.

2. Ultrasound-guided charcoal tattooing on cytology-confirmed ALN
-----------------------------------------------------------------

Prior to NCT, the main breast tumor was marked with a metallic clip and then the cytology-proven metastatic ALN was tattooed with charcoal suspension (Charcotrace, Phebra, Sydney, Australia) through ultrasound-guidance by a radiologist (M.J.K.) who had more than 14 years of specialized experience in breast imaging. To minimize obstacles to pathologic examination, the charcoal was mainly injected into the capsular area of the metastasis-confirmed ALN and a needle-point injection track was made from the ALN to the skin of the axilla. A median dose of 0.5 mL (range, 0.2 to 0.8 mL) was used for node tattooing.

3. Response to NCT and clinicopathological factors
--------------------------------------------------

After four cycles of anthracycline followed by taxane-containing NCT, the responses of the primary tumor and nodes were comprehensively evaluated using clinical and radiological examinations, mainly with ultrasound or breast magnetic resonance images. For cases with human epidermal growth factor receptor 2 (HER2)‒positive disease, trastuzumab was incorporated into the NCT regimens. According to the Response Evaluation Criteria in Solid Tumors ver. 1.1, tumor response to NCT was considered as complete or partial response and non-response was defined with stable or progressive disease. The ALN response to NCT was defined with the disappearance of metastatic ALNs or no suspicious imaging findings in the axilla. Nodal non-response was considered when suspicious findings in the axilla remained after completion of NCT.

Pathologic stages were based on the *AJCC Cancer Staging Manual*, seventh edition \[[@b13-crt-2017-210]\]. The modified Scarff-Bloom-Richardson grading system was used for histologic grading. Tumors with ≥ 1% nuclear-stained cells by immunohistochemistry using core needle biopsy specimens were considered positive for estrogen receptor (ER) and progesterone receptor (PR) according to the American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guidelines \[[@b14-crt-2017-210]\]. HER2 staining was scored as 0, 1+, 2+, or 3+ according to the ASCO/CAP guidelines \[[@b15-crt-2017-210]\]. In cases with HER2 2+ results, silver *in situ* hybridization (SISH) was performed using the INFORM HER2 Dual ISH DNA Probe Cocktail Assay (Ventana Medical Systems, Tucson, AZ) with an automated slide stainer according to the manufacturer's protocols. *HER2* gene amplification was defined with a *HER2* gene/chromosome 17 copy number ratio ≥ 2.0 or a *HER2* gene/chromosome 17 copy number ratio \< 2.0 with an average *HER2* copy number ≥ 6.0 signals/cell according to the ASCO/CAP guidelines \[[@b15-crt-2017-210]\]. An immunohistochemistry score of 3+ or gene amplification by SISH was considered HER2-positive. During the study period, Ki-67 staining was mainly performed on post-treatment surgical specimens for residual carcinomas in our institution and was not investigated in the present study.

Based on ER, PR, HER2, and histologic grade findings, molecular phenotypes were categorized into the following four subgroups: luminal A (ER-positive and/or PR-positive, HER2-negative and grade 1 or 2), luminal B (ER-positive and/or PR-positive, HER2-negative and grade 3; or ER-positive and/or PR-positive, and HER2-positive), HER2-enriched (ER-negative, PR-negative, and HER2-positive), and triple-negative breast cancer (TNBC) (ER-negative, PR-negative, and HER2-negative).

4. SLNB, axillary surgery, and pathologic assessment
----------------------------------------------------

SLNs were detected using a combination of radioisotopes and blue dye techniques except for one detected with a radioisotope alone. In brief, 0.5 mCi ^99m^Tc-Phytate (Korea Atomic Energy Research Institute, Daejeon, Korea) was diluted in 0.5 mL saline and injected into the subcutaneous layer of the areolar tissue in the direction of the main primary tumor at the Department of Nuclear Medicine on the day of surgery. In the operation room just before surgery was initiated, 0.8% indigo carmine dye (Carmine, Korea United Pharm Inc., Seoul, Korea) was injected into the periareolar area followed by a massage of the injection site. SLNs were excised and defined as hot and/or blue-colored nodes with a handheld gamma probe (Neoprobe Gamma Detection System, Neoprobe Corp., Dublin, OH) at gross visual inspection or with a radioactive count of ≥ 10% of the ex vivo count of the hottest node. During SLNB, clinically palpable cold or non-blue axillary nodal tissues were also excised and categorized as axillary sampling. Charcoal-tattooed ALN and track were removed during axilla surgery and included in the SLNB or axillary sampling procedures. SLNs and axillary sampling tissues were then sent to frozen section analysis. After SLNB and/or axillary sampling, the decision to perform further concomitant completion level I/II ALND was made taking into account patient' consent, initial nodal burden, node responses during and after NCT, or frozen section results of SLNB and/or axillary sampling.

All excised ALNs including SLNs were subjected to routine pathological examinations, which included hematoxylin and eosin staining with or without immunohistochemistry for cytokeratin in accordance with previously published recommendations \[[@b16-crt-2017-210]\]. ALNs were considered positive if metastatic foci were \> 0.2 mm and/or \> 200 tumor cells (≥ ypN1mi) according to the *AJCC Cancer Staging Manual*, seventh edition \[[@b13-crt-2017-210]\]. Any nodes with isolated metastatic foci of ≤ 0.2 mm were considered negative \[ypN0(i+)\], but were not considered to have achieved a node pathologic complete response (pCR). Regarding primary tumor responses to NCT, the absence of *in situ* or invasive carcinomas (ypT0) or residual *in situ* carcinoma alone without invasive disease (ypTis) constituted a tumor pCR.

5. Statistical analysis
-----------------------

The detection of charcoal-tattooed node was investigated and its association with the detection of SLNs was analyzed. Detection failure of SLNs was defined as an inability to identify hot and/or blue nodes by lymphoscintigraphy or gamma probe with visual inspection. Sensitivity was calculated by dividing true positive (TP) findings by TP plus false-negative (FN) findings. FNR was defined as the proportion of patients with negative SLNs who subsequently had metastatic ALNs among patients with ≥ 1 positive lymph node. NPV was calculated by dividing true negative (TN) findings by TN plus FN findings. Accuracy was defined as the proportion of patients with TP or TN among patients with successful SLNB. The significances of differences in SLNB performance of subgroups and in clinicopathological parameters between groups were evaluated using the chi-square test or Fisher exact test. The Mann-Whitney U test was used to compare the median values of continuous numerical data. All statistical tests were two-sided, and p \< 0.05 was considered statistically significant. SPSS ver. 23.0 (IBM Corp., Armonk, NY) and SAS ver. 9.4 (SAS Inc., Cary, NC) were used for analysis.

6. Ethical statement
--------------------

This study was approved by the Institutional Review Board (IRB) of Severance Hospital, Yonsei University Health System, Seoul, Korea (IRB No. 4-2015-0465) and registered to the Clinical Research Information Service (CRIS, <http://cris.nih.go.kr/cris/index.jsp>; No. KCT0002370), Korea. Written informed consent was obtained from all patients prior to study entry.

Results
=======

1. Patient characteristics and ultrasound-guided charcoal tattooing procedure
-----------------------------------------------------------------------------

The mean age of 20 patients was 52.3±10.9 years (range, 34 to 70 years) at diagnosis. The mean size of the main primary tumor at presentation was 3.1±1.8 cm (range, 1.2 to 8.4 cm). [Table 1](#t1-crt-2017-210){ref-type="table"} shows the clinicopathological characteristics and treatment patterns of the enrolled patients. No significant side effects or complications occurred during charcoal tattooing of metastatic ALN. After finishing the tattooing procedure, 16 patients (80%) underwent NCT on the very day that charcoal tattooing was performed and the time interval between charcoal tattooing and NCT ranged from 0 to 5 days. The median time interval between charcoal tattooing and surgery was 181 days (range, 165 to 197 days).

Final permanent pathology of breast and ALNs is presented in [Table 1](#t1-crt-2017-210){ref-type="table"}. Preoperative imaging studies of three patients with initially suspicious non-axillary regional lymph nodes showed no radiological evidence of non-axillary regional metastasis after completion of NCT. Therefore, when pathologic results of the breast and axilla were considered, both tumor and nodal pCR were determined in six patients (30.0%). There was no statistical difference in the nodal pCR rate according to the type of axillary surgery (ALND 41.7% vs. axillary sampling 62.5%, p=0.650) ([Table 1](#t1-crt-2017-210){ref-type="table"}).

2. Axillary surgery and diagnostic performance of SLNB
------------------------------------------------------

One or more hot and/or blue SLNs were detected in all patients (detection rate, 100%). The median number of SLNs and total ALNs (SLNs+non-sentinel ALNs) retrieved was 3.0 (range, 1 to 12) and 10.0 (range, 4 to 18), respectively. The median number of non-sentinel ALNs excised was 4.5 (range, 0 to 15). The number of pathologically retrieved nodes in two patients who underwent SLNB alone was four and 10, respectively. During axillary surgery, charcoal-tattooed ALN and track were easily identified by visual inspection and excised in all patients (detection rate of tattooed node, 100%). According to the type of axillary surgery, the median number of SLNs was not different (n=3 in each group, p=0.624), but the median number of non-sentinel ALNs was significantly larger in the ALND group; therefore, the median number of total ALNs removed was significantly higher in the ALND group (ALND, 13 \[range, 7 to 18\] vs. axillary sampling, 4.5 \[range, 4 to 10\]; p \< 0.001).

[Table 2](#t2-crt-2017-210){ref-type="table"} compares SLNB results of removing hot and/or blue SLNs with the final ALN status. In addition to hot and/or blue SLNs, charcoal-tattooed node was calculated together as the modified SLNB. The diagnostic performance of the modified SLNB showed the highest values as follows: sensitivity, 100%; FNR, 0.0%; NPV, 100%; and accuracy, 100%.

Overall diagnostic performance of SLNB is presented in [Table 3](#t3-crt-2017-210){ref-type="table"} including subgroups. When more SLNs were excised, the sensitivity, NPV, and accuracy improved and FNR decreased, although statistical significance was not demonstrated. Similarly, wider axillary surgery or favorable nodal response was associated with improved diagnostic performance of SLNB. Better performance was exhibited in patients with luminal A or B subtypes than in those with non-luminal (HER2-enriched or TNBC) subtypes with borderline significance.

3. Association between sentinel and tattooed lymph nodes
--------------------------------------------------------

Charcoal-tattooed ALN was among the hot and/or blue SLNs in 15 patients (75.0%) but removed during cold and non-blue axillary nodes sampling in five cases (25.0%). Among 15 patients with concordance between the tattooed node and SLNs, eight (53.3%) showed residual metastatic disease in the charcoal-tattooed ALN. The other seven patients (46.7%) were determined to have negative conversion of the tattooed node and finally achieved nodal pCR. Among five patients with discordance between the tattooed ALN and SLNs, three (60.0%) showed negative sentinel and tattooed nodes and finally achieved nodal pCR. Of the remaining two patients, one 61-year-old patient showed that three SLNs detected were negative, but the charcoal-tattooed non-sentinel ALN showed residual metastasis ([Fig. 1](#f1-crt-2017-210){ref-type="fig"}). In the other 59-year-old patient, only one SLN was retrieved. Frozen section and permanent pathology of the SLN confirmed the presence of a few atypical cells and isolated tumor cells with a maximal diameter of 100 μm \[ypN0(i+)\], respectively. Subsequently, ALND was performed and metastatic carcinomas in four out of 12 ALNs were found including micrometastasis (450 μm) in the tattooed ALN.

Regarding the intensity order of the uptaken radioisotope, the tattooed node was the hottest in eight patients, the second hottest in three, and the third hottest in four. When clinicopathological characteristics of patients with concordant SLNs and tattooed node were compared to those of patients with discordant findings, no statistically significant parameters were identified ([Table 4](#t4-crt-2017-210){ref-type="table"}).

Discussion
==========

In patients with clinically or histopathologically node-positive disease at presentation, SLNB can decrease morbidity while increasing quality of life by allowing ALND to be omitted when the axilla is converted to clinically node-negative status after NCT, similar benefits to those proven in initially node-negative patients \[[@b17-crt-2017-210],[@b18-crt-2017-210]\]. However, the diagnostic performance and oncological safety of SLNB has been evolving and long-term follow-up results are required to clearly define the role of SLNB in these patients. Recently, the SENTINA, ACOSOG Z1071, and SN FNAC trials showed SLNB being performed in this setting under somewhat different protocols and the results of these studies found the following technical issues to be conclusively associated with SLNB accuracy: marking of biopsied ALNs, use of dual tracers, numbers of SLNs retrieved, and immunohistochemical evaluation \[[@b4-crt-2017-210],[@b19-crt-2017-210]\]. The National Comprehensive Cancer Network guidelines recommend either type of axillary surgery as a category 2B and also state the technical considerations \[[@b9-crt-2017-210]\].

In the present study, hot and/or blue SLNs as well as black-tattooed ALN and track could be detected in all patients after NCT within a median duration of 6 months, fulfilling the technical feasibility of node tattooing without significant morbidity. Similarly, black ink could be identified intraoperatively up to an average 130 days after tattooing in a report of Choy et al. \[[@b11-crt-2017-210]\]. Three or more SLNs were removed in 18 patients (90.0%) and the tattooed ALN was included in the SLNs of 15 patients (75.0%). On gross inspection, the blue dye of the black tattooed nodes was faint in some cases \[[@b11-crt-2017-210]\], but subtle different coloring or the direction of the running tracks guided discrimination between sentinel and non-sentinel nodes with the assistance of radioisotopes ([Fig. 2](#f2-crt-2017-210){ref-type="fig"}). Pathologic examination was not encumbered by the black pigments on the slides.

More importantly, improved diagnostic performance of SLNB was again demonstrated by marking of metastatic node with charcoal tattoo even small size of this study and inability to calculate the number of TN due to 40% of our cases without ALND. In addition, invasive localization procedure is not required preoperatively and it is not necessary to verify removal of a clip or radioactive seed in surgical specimen during surgery using specimen mammography. In patients with much favorable nodal response to NCT who are a potential candidate of SLNB, even specialized radiologists may have difficulty to detect a clip in an ALN by ultrasound and mammographic detection or targeting might be performed before surgery. However, black-color charcoal was easily detected during surgery without any additional mechanical device or equipment. Clinically negligible risk of charcoal migration or absorption was presented in this study and additional radiation hazard did not exist. However, long-term benefits and complications of charcoal tattooing should be further validated using large cohort studies.

According to predefined SLNB and pathological node response, the FNR of this study with a small cohort was worse than that of a prior meta-analyses \[[@b20-crt-2017-210],[@b21-crt-2017-210]\]. However, when the protocols of the SN FNAC study were followed, the performance of SLNB was comparable when ypN0(i+) was considered node-positive \[[@b8-crt-2017-210]\]. Although the clinical relevance of very small residual nodal disease after NCT remains unclear \[[@b22-crt-2017-210]\], the more number of SLNs retrieved or the wider type of axillary surgery increased the accuracy of SLNB. Similar to this study, Mamtani et al. \[[@b23-crt-2017-210]\] reported that at least three SLNs including abnormally palpable nodes during surgery could be removed in 86% of patients, but the SENTINA and ACOSOG Z1071 studies reported that approximately one-third to one-half of patients could have ≥ 3 SLNs retrieved, respectively \[[@b6-crt-2017-210],[@b7-crt-2017-210]\]. It is challenging to determine whether ≥ 3 SLNs can be retrieved in the majority of patients after NCT.

Persistently suspicious ALN metastasis after completion of NCT is not an indication for SLNB in initially node-positive patients \[[@b9-crt-2017-210],[@b18-crt-2017-210]\]. In the ACOSOG Z1071 trial, approximately 70% of patients presented normalized nodal features on axillary ultrasound after NCT and these patients showed acceptable SLNB performance with a FNR of 9.8% \[[@b24-crt-2017-210]\]. Current cohorts with favorable nodal response to NCT seen on preoperative work-ups also demonstrated better performance of SLNB with tattooing. Therefore, axillary restaging by image modalities after NCT could inform patient selection and further improvements of optimal techniques should be investigated in this setting \[[@b19-crt-2017-210]\]. In addition, molecular phenotypes are well-known predictive factors of NCT response. Although the small sample size in this study was not conclusive, luminal subtypes showed better performance than non-luminal subtypes in contrast to findings from prior studies \[[@b3-crt-2017-210],[@b25-crt-2017-210]\]. More research is needed to answer the remaining questions.

Basically, SLNB should be used to excise hot and/or blue nodes detected by dual tracers as well as suspicious enlarged cold and non-blue ALNs intraoperatively in both adjuvant and neoadjuvant settings \[[@b26-crt-2017-210],[@b27-crt-2017-210]\]. In the present study, 11 patients underwent suspicious ALN sampling including five tattooed node excisions and of them, three (27.3%) showed additional two residual macronodal and one residual micronodal metastasis from the sampled ALNs. According to the practically recommended SLNB technique, the performance of the modified SLNB in this study was the best. Our results again emphasize the removal of suspiciously cold or non-blue ALNs during SLNB. However, considering the chance of non-palpable partial nodal response to NCT and the need for balance between surgical morbidity and diagnostic accuracy, charcoal marking at diagnosis followed by excision of the biopsy-proven ALN after NCT, so called targeted axillary dissection, can be one of the best ways to improve the performance in concordance with suggestions from the ACOSOG Z1071 study \[[@b10-crt-2017-210],[@b28-crt-2017-210]\]. Furthermore, there was no significant difference in clinicopathological parameters between patients with tattooed ALN included in SLNB and axillary sampling, suggesting the importance of the marking technique itself to achieve successful targeted axillary dissection.

Patterns of lymphatic drainage to SLNs in breast cancer are known to be individual characteristic and are even detected in internal mammary chains by lymphoscintigraphy \[[@b29-crt-2017-210]\]. Langer's axillary arch, an anatomical variation, is found in 7% to 10% of cases during surgery or by preoperative diagnosis and can affect SLNB \[[@b30-crt-2017-210]\]. A 47-year-old woman who underwent SLNB guided by only a radioisotope had a left axillary arch noted in her initial diagnostic work-up, but her tattooed node with the third intensity of modest uptake was unexpectedly located in the deep portion of the axilla during surgery, which might have been missed if done without caution ([Fig. 3](#f3-crt-2017-210){ref-type="fig"}). Fortunately, guided by the tattoo track, the biopsy-proven tattooed SLN could be easily removed and technical mistakes were prevented. Although the clinical impact of the axillary arch on SLNB in this setting is currently uncertain, these rare circumstances can be happen to anyone and should be kept in mind.

In conclusion, our initial experience with charcoal tattooing of cytology-confirmed metastatic ALN at presentation showed technical feasibility without significant morbidity in breast cancer patients treated with NCT. SLNB using dual tracers after NCT is not limited by positive node tattooing and has been demonstrated to improve accuracy. Furthermore, invasive preoperative localization is not additionally required to detect the marked node. The tattooing procedure can prevent technical errors during SLNB. A multicenter study with a large study population is necessary to determine the clinical implications of the node-tattooing technique including long-term side effects and its oncological safety in this setting.
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![Gross and microscopic findings of a charcoal-tattooed lymph node in a patient presenting with a false-negative sentinel lymph node biopsy using dual tracers. (A) Gross picture of a retrieved charcoal-tattooed axillary lymph node. (B) *Ex vivo* radioisotope counts of the tattooed node showing minimal uptake (value, 35). (C) Microscopic photograph of residual metastatic carcinomas and charcoal pigments in the tattooed axillary node (H&E staining, ×100).](crt-2017-210f1){#f1-crt-2017-210}

![Intraoperative photographs and pathologic slides of a sentinel lymph node. (A) Charcoal tattoo (black arrow) and blue dye (blue arrow) tracks during axillary surgery. (B) Excised sentinel node marked with the tattoo and blue dye. Low-power field (H&E staining, ×20) (C) and high-power field (H&E staining, ×100) (D) microscopic views show tattoo pigments with no residual metastatic carcinoma in the sentinel node.](crt-2017-210f2){#f2-crt-2017-210}

![Images and tattooed sentinel node of a patient with an axillary arch. (A) The ^18^F-fluorodeoxyglucose (FDG) positron emission tomography--computed tomography (PET-CT) scan shows increased FDG uptake by the metastatic axillary lymph node in the level I left axilla (arrow). (B) The PET-CT scan demonstrates the left axillary arch that is also known as the axillopectoral muscle (double arrow). (C) The hot and tattooed sentinel lymph node is retrieved.](crt-2017-210f3){#f3-crt-2017-210}

###### 

Clinicipathological characteristics of the enrolled patients

  Parameter                               No. of patients (%)
  --------------------------------------- ---------------------
  **Age (yr)**                            
   ≤ 50                                   11 (55.0)
   \> 50                                  9 (45.0)
  **BMI (kg/m^2^)**                       
   ≤ 25                                   15 (75.0)
   \> 25                                  5 (25.0)
  **Laterality**                          
   Left                                   13 (65.0)
   Right                                  7 (35.0)
  **Location of the main lesion**         
   Upper outer quadrant                   7 (35.0)
   Upper inner quadrant                   4 (20.0)
   Upper central area                     2 (10.0)
   Mediocentral area                      2 (10.0)
   Lower outer quadrant                   2 (10.0)
   Lower inner quadrant                   1 (5.0)
   Lower central area                     1 (5.0)
   Subareolar area                        1 (5.0)
  **Histologic type**                     
   IDC-NOS                                19 (95.0)
   Mucinous carcinoma                     1 (5.0)
  **Clinical tumor stage at diagnosis**   
   cT1                                    6 (30.0)
   cT2                                    11 (55.0)
   cT3                                    3 (15.0)
  **Clinical node stage at diagnosis**    
   cN1                                    12 (60.0)
   cN2                                    5 (25.0)
   cN3                                    3 (15.0)
  **Regimens of NCT**                     
   AC--wP±H                               9 (45.0)
   AC--T±H                                11 (55.0)
  **Tumor response to NCT**               
   Response                               14 (70.0)
   Non-response                           6 (30.0)
  **Node response to NCT**                
   Response                               11 (55.0)
   Non-response                           9 (45.0)
  **Pathologic tumor stage**              
   ypT0-is                                6 (30.0)
   ypT1-2                                 14 (70.0)
  **Pathologic node stage**               
   ypN0                                   10 (50.0)
   ypN1-2                                 10 (50.0)
  **Pathologic TNM stage**                
   Stage 0                                6 (30.0)
   Stage 1                                4 (20.0)
   Stage 2                                7 (35.0)
   Stage 3                                3 (15.0)
  **Histologic grade**                    
   I                                      3 (15.0)
   II                                     13 (65.0)
   III                                    4 (20.0)
  **Lymphovascular invasion**             
   Absent                                 15 (75.0)
   Present                                5 (25.0)
  **Perinodal extension**                 
   Absent                                 15 (75.0)
   Present                                5 (25.0)
  **Estrogen receptor**                   
   Negative                               6 (30.0)
   Positive                               14 (70.0)
  **Progesterone receptor**               
   Negative                               8 (40.0)
   Positive                               12 (60.0)
  **HER2**                                
   Negative                               15 (75.0)
   Positive                               5 (25.0)
  **Molecular phenotype**                 
   Luminal A                              10 (50.0)
   Luminal B                              4 (20.0)
   HER2-enriched                          2 (10.0)
   TNBC                                   4 (20.0)
  **Type of breast surgery**              
   Breast-conserving surgery              11 (55.0)
   Total mastectomy                       9 (45.0)
  **Type of axillary surgery**            
   SLNB alone                             2 (10.0)
   SLNB+axillary sampling                 6 (30.0)
   SLNB+ALND                              12 (60.0)

BMI, body mass index; IDC-NOS, invasive ductal carcinoma-not otherwise specified; NCT, neoadjuvant chemotherapy; AC, anthracycline followed by cyclophosphamide; wP, weekly paclitaxel; H, trastuzumab; T, docetaxel; TNM, tumor node metastasis; HER2, human epidermal growth factor receptor 2; TNBC, triple-negative breast cancer; SLNB, sentinel lymph node biopsy; ALND, axillary lymph node dissection.

###### 

Results of SLNB and axillary surgery

  Parameter                                                          Final ALN status after NCT   Total        
  ------------------------------------------------------------------ ---------------------------- ------- ---- ----
  **SLNB**                                                                                                     
   Positive                                                          3                            5       \-   8
   Negative                                                          2                            \-      10   12
  **Modified SLNB^[a)](#tfn1-crt-2017-210){ref-type="table-fn"}^**                                             
   Positive                                                          4                            6       \-   10
   Negative                                                          0                            \-      10   10

SLNB, sentinel lymph node biopsy; ALN, axillary lymph node; NCT, neoadjuvant chemotherapy.

Modified SLNB is the final results of hot or blue-colored sentinel lymph nodes and initial cytology-proven, charcoal-tattooed lymph node excised during axillary sampling procedure.

###### 

Diagnostic performance of SLNB in all and subgroups of patients

  Parameter                      Sensitivity (%)   FNR (%)    NPV (%)      Accuracy (%)
  ------------------------------ ----------------- ---------- ------------ --------------
  **Overall (n=20)**             80.0              20.0       83.3         90.0
  **95% CI**                     55.2-100.0        0.0-44.8   62.2-100.0   76.9-100.0
  **No. of retrieved SLNs**                                                
   ≤ 2 (n=2)                     0.0               100.0      50.0         50.0
   3 (n=11)                      75.0              25.0       87.5         90.9
   ≥ 4 (n=7)                     100.0             0.0        100.0        100.0
   p-value                       0.089             0.089      0.576        0.305
  **Type of axillary surgery**                                             
   Axillary sampling (n=8)       66.7              33.4       83.3         87.5
   ALND (n=12)                   85.7              14.3       83.3         91.7
   p-value                       \> 0.999          \> 0.999   \> 0.999     \> 0.999
  **Node response to NCT**                                                 
   Response (n=11)               100.0             0.0        100.0        100.0
   Non-response (n=9)            71.4              28.6       50.0         77.8
   p-value                       \> 0.999          \> 0.999   0.091        0.190
  **Molecular phenotype**                                                  
   Luminal (n=14)                100.0             0.0        100.0        100.0
   Non-luminal (n=6)             33.3              66.7       60.0         66.7
   p-value                       0.067             0.067      0.152        0.079

SLNB, sentinel lymph node biopsy; FNR, false-negative rate; NPV, negative predictive value; CI, confidence interval; SLNs, sentinel lymph nodes; ALND, axillary lymph node dissection; NCT, neoadjuvant chemotherapy.

###### 

Clinicopathological characteristics between patients whose SLNs concordantly included a charcoal-tattooed lymph node and those not

  Parameter                               Concordant (n=15)   Discordant (n=5)   p-value^[a)](#tfn2-crt-2017-210){ref-type="table-fn"}^
  --------------------------------------- ------------------- ------------------ --------------------------------------------------------
  **Age (yr)**                                                                   
   ≤ 50                                   10 (66.7)           1 (20.0)           0.127
   \> 50                                  5 (33.3)            4 (80.0)           
  **BMI (kg/m^2^)**                                                              
   ≤ 25                                   12 (80.0)           3 (60.0)           0.560
   \> 25                                  3 (20.0)            2 (40.0)           
  **Laterality**                                                                 
   Left                                   10 (66.7)           3 (60.0)           \> 0.999
   Right                                  5 (33.3)            2 (40.0)           
  **Clinical tumor stage at diagnosis**                                          
   cT1                                    3 (20.0)            3 (60.0)           0.131
   cT2-3                                  12 (80.0)           2 (40.0)           
  **Clinical node stage at diagnosis**                                           
   cN1                                    10 (66.7)           2 (40.0)           0.347
   cN2-3                                  5 (33.3)            3 (60.0)           
  **Regimens of NCT**                                                            
   AC--wP±H                               7 (46.7)            2 (40.0)           \> 0.999
   AC--T±H                                8 (53.3)            3 (60.0)           
  **Tumor response to NCT**                                                      
   Response                               10 (66.7)           4 (80.0)           \> 0.999
   Non-response                           5 (33.3)            1 (20.0)           
  **Node response to NCT**                                                       
   Response                               9 (60.0)            2 (40.0)           0.617
   Non-response                           6 (40.0)            3 (60.0)           
  **Pathologic tumor stage**                                                     
   ypT0-is                                4 (26.7)            2 (40.0)           0.613
   ypT1-2                                 11 (73.3)           3 (60.0)           
  **Pathologic node stage**                                                      
   ypN0                                   7 (46.7)            3 (60.0)           \> 0.999
   ypN1-2                                 8 (53.3)            2 (40.0)           
  **Pathologic TNM stage**                                                       
   Stage 0                                4 (26.7)            2 (40.0)           0.613
   Stage 1-3                              11 (73.3)           3 (60.0)           
  **Histologic grade**                                                           
   I/II                                   12 (80.0)           4 (80.0)           \> 0.999
   III                                    3 (20.0)            1 (20.0)           
  **Lymphovascular invasion**                                                    
   Absent                                 11 (73.3)           4 (80.0)           \> 0.999
   Present                                4 (26.7)            1 (20.0)           
  **Perinodal extension**                                                        
   Absent                                 11 (73.3)           4 (80.0)           \> 0.999
   Present                                4 (26.7)            1 (20.0)           
  **Estrogen receptor**                                                          
   Negative                               3 (20.0)            3 (60.0)           0.131
   Positive                               12 (80.0)           2 (40.0)           
  **Progesterone receptor**                                                      
   Negative                               5 (33.3)            3 (60.0)           0.347
   Positive                               10 (66.7)           2 (40.0)           
  **HER2**                                                                       
   Negative                               11 (73.3)           4 (80.0)           \> 0.999
   Positive                               4 (26.7)            1 (20.0)           
  **Molecular phenotype**                                                        
   Luminal A                              8 (53.3)            2 (40.0)           0.319
   Luminal B                              4 (26.7)            0                  
   HER2-enriched                          1 (6.7)             1 (20.0)           
   TNBC                                   2 (13.3)            2 (40.0)           
  **Type of breast surgery**                                                     
   Breast-conserving surgery              9 (60.0)            2 (40.0)           0.617
   Total mastectomy                       6 (40.0)            3 (60.0)           
  **Type of axillary surgery**                                                   
   SLNB±axillary sampling                 6 (40.0)            2 (40.0)           \> 0.999
   SLNB+ALND                              9 (60.0)            3 (60.0)           

SLN, sentinel lymph node; BMI, body mass index; NCT, neoadjuvant chemotherapy; AC, anthracycline followed by cyclophosphamide; wP, weekly paclitaxel; H, trastuzumab; T, docetaxel; HER2, human epidermal growth factor receptor 2; TNBC, triple-negative breast cancer; SLNB, sentinel lymph node biopsy; ALND, axillary lymph node dissection.

p-value was calculated by the Fisher exact test.

[^1]: Seho Park and Ja Seung Koo contributed equally to this work.
